![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
3-Adrenoceptor Agonist, on Bladder FunctionInstitute for Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan (T.T., M.U., S.S., Te.M., I.N., Ta.M., M.S., K.M.); and Department of Urology, Fukushima Medical University, Fukushima, Japan (H.U., O.M.)
We evaluated the pharmacological characteristics of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]-ethyl} acetanilide (YM178). YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human
3-adrenoceptor (AR). The half-maximal effective concentration (EC50) value was 22.4 nM. EC50 values of YM178 for human
1- and
2-ARs were 10,000 nM or more, respectively. The ratio of intrinsic activities of YM178 versus maximal response induced by isoproterenol (nonselective
-AR agonist) was 0.8 for human
3-ARs, 0.1 for human
1-ARs, and 0.1 for human
2-ARs. The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (
3-AR agonist). EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 106 M CCh were 5.1 and 1.4 µM, respectively, whereas those in human bladder strips precontracted with 107 M CCh were 0.78 and 0.28 µM, respectively. In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats. These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.
Address correspondence to: Dr. Toshiyuki Takasu, Pharmacology Research Laboratories, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585 Japan. E-mail: toshiyuki.takasu{at}jp.astellas.com
This article has been cited by other articles:
![]() |
K.-E. Andersson Prospective pharmacologic therapies for the overactive bladder Therapeutic Advances in Urology, June 1, 2009; 1(2): 71 - 83. [Abstract] [PDF] |
||||
![]() |
E. S. R. Lashinger, M. S. Steiginga, J. P. Hieble, L. A. Leon, S. D. Gardner, R. Nagilla, E. A. Davenport, B. E. Hoffman, N. J. Laping, and X. Su AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome Am J Physiol Renal Physiol, September 1, 2008; 295(3): F803 - F810. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hicks, G. P. McCafferty, E. Riedel, N. Aiyar, M. Pullen, C. Evans, T. D. Luce, R. W. Coatney, G. C. Rivera, T. D. Westfall, et al. GW427353 (Solabegron), a Novel, Selective beta3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 202 - 209. [Abstract] [Full Text] [PDF] |
||||